BioCryst Pharmaceuticals (BCRX) director Galson received 15,294 shares
Insider transactions reported
Steven K Galson (director at BioCryst Pharmaceuticals Inc., BCRX) reported that they received 15,294 shares on Jun 11, 2026. After these transactions the filing shows 27,794 shares held directly.
- Reporting person
- Galson Steven K
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Grant or award (A) | Common Stock1 | +15,294 | - | - | 27,794 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Grant or award (A) | Automatic Stock Option GrantOn 33,540 Common Stock3 | +33,540 | - | - | 33,540 direct |
Holdings before and after
- Common Stock: 12,500 to 27,794 direct
- Automatic Stock Option Grant: 0 to 33,540 direct
Other positions listed
- Common Stock: 58,371 indirect, By Trust
Footnotes from the filing
- 1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the Director Compensation Policy ), which will vest on the first anniversary of the date of grant.
- 2. On July 23, 2025, the Reporting Person transferred 12,491 shares to a living trust for no consideration. The Reporting Person is an indirect beneficial owner of the shares held by the trust.
- 3. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Galson report in this BCRX Form 4?
Steven K Galson (director at BioCryst Pharmaceuticals Inc., BCRX) reported that they received 15,294 shares on Jun 11, 2026. After these transactions the filing shows 27,794 shares held directly.
How many BCRX shares does Galson hold after this filing?
The filing shows 27,794 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for BCRX
Across the 26 sessions after earlier BCRX headlines, the stock closed higher 14 times and lower 12 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BCRX | SPY |
|---|---|---|---|
| Jun 10, 2026 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.7% | -1.6% |
| May 27, 2026 | BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting | +7.7% | -0.0% |
| May 13, 2026 | BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 | +9.1% | +0.6% |
| May 6, 2026 | BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update | -2.2% | +1.4% |
| May 5, 2026 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.8% | +0.8% |
| May 4, 2026 | BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema | +0.1% | -0.4% |
Earlier insider filings at BCRX
- Jun 15, 2026Director Levin Alan G was granted 15,294 shares, increasing direct ownership by 24% to 79,565 units (SEC Form 4)
- Jun 15, 2026Director Frank Steven was granted 15,294 shares, increasing direct ownership by 76% to 35,459 units (SEC Form 4)
- Jun 15, 2026Director Sanders Machelle was granted 15,294 shares, increasing direct ownership by 50% to 45,936 units (SEC Form 4)
- Jun 15, 2026Director Milano Vincent was granted 15,294 shares, increasing direct ownership by 16% to 108,483 units (SEC Form 4)
- Jun 15, 2026Director Stonehouse Jon P was granted 15,294 shares, increasing direct ownership by 1% to 1,339,775 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1994
Follow BCRX and get a push notification the moment its next story breaks.